Biocon share price rises nearly 6% despite 52% dip in Q2 profit
Biocon reported results.
· Business Standard Mkts
Biocon reported a 52% dip in Q2 consolidated net profit at ₹41 crore, while revenue from operations grew by 2%. The stock recently hit a 52-week low of ₹318.40 on the NSE.
The analysis
Biocon reported ₹41 crore and ₹318.40, with movement of 6%, 2% and 52% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +5.0% on the day at ₹361.55, and has returned -18.4% over three months. It sits 18% below its 52-week high. The pharma & healthcare sector has moved +1.0% over the same period, so Biocon is running 19.4 points behind its peers.
For Biocon, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
- With NSE involved, this carries a regulatory dimension that can outlast the immediate market reaction.
Market context
- In focus: Biocon (BIOCON), in Pharma & Healthcare.
- Over three months: Biocon -18.4% against Pharma & Healthcare +1.0% (19.4 points behind).
- Trading well above normal today: Biocon at 2.0 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| BioconBIOCON · Pharma & Healthcare | ₹361.55 | +5.0% | -7.1% | -18.4% | -18.0% | 2.0× | — |
Pharma & Healthcare
1M +2.6% · 3M +1.0%
Biocon
Prices as of 5 Nov 2026, 15:01 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Biocon Q2 profit halves to ₹41 crore as delayed shipments weigh on margins
Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 crore
Q2 Results Live Updates: LG Electronics, Bharti Airtel, Abbott India, Astral, Bharat Forge, Berger Paints, Emami, Fortis Healthcare Earnings In Focus
Zydus Lifesciences Q2 results: Net profit falls 26.6% to ₹925.5 crore
Alembic Pharma shares hit 20% upper circuit after 81% YoY rise in Q2 PAT